816
Views
0
CrossRef citations to date
0
Altmetric
Acceptance & Hesitation

Knowledge about, attitudes toward and acceptance and predictors of intention to receive the mpox vaccine among cancer patients in China: A cross-sectional survey

, , , , , & show all
Article: 2337157 | Received 02 Feb 2024, Accepted 27 Mar 2024, Published online: 21 Apr 2024

References

  • Kumar N, Acharya A, Gendelman HE, Byrareddy SN. The 2022 outbreak and the pathobiology of the monkeypox virus. J Autoimmun. 2022;131:102855. doi:10.1016/j.jaut.2022.102855.
  • Alakunle E, Moens U, Nchinda G, Okeke MI. Monkeypox virus in Nigeria: infection biology, epidemiology, and evolution. Viruses. 2020;12:12. doi:10.3390/v12111257.
  • Laurenson-Schafer H, Sklenovska N, Hoxha A, Kerr SM, Ndumbi P, Fitzner J, Almiron M, de Sousa LA, Briand S, Cenciarelli O, et al. Description of the first global outbreak of mpox: an analysis of global surveillance data. Lancet Glob Health. 2023;11:1012–11. doi:10.1016/S2214-109X(23)00198-5.
  • Isidro J, Borges V, Pinto M, Sobral D, Santos JD, Nunes A, Mixao V, Ferreira R, Santos D, Duarte S, et al. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat Med. 2022;28:1569–72. doi:10.1038/s41591-022-01907-y.
  • Halani S, Mishra S, Bogoch II. The monkeypox virus. CMAJ. 2022;194:E844. doi:10.1503/cmaj.220795.
  • McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis. 2014;58:260–7. doi:10.1093/cid/cit703.
  • Reynolds MG, McCollum AM, Nguete B, Shongo LR, Petersen BW. Improving the care and treatment of monkeypox patients in low-resource settings: applying evidence from contemporary biomedical and smallpox biodefense research. Viruses. 2017;9:380. doi:10.3390/v9120380.
  • Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. Prevention and treatment of Monkeypox. Drugs. 2022;82:957–63. doi:10.1007/s40265-022-01742-y.
  • Russo AT, Grosenbach DW, Chinsangaram J, Honeychurch KM, Long PG, Lovejoy C, Maiti B, Meara I, Hruby DE. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther. 2021;19:331–44. doi:10.1080/14787210.2020.1819791.
  • Chan-Tack K, Harrington P, Bensman T, Choi SY, Donaldson E, O’Rear J, McMillan D, Myers L, Seaton M, Ghantous H, et al. Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration’s evaluation. Antiviral Res. 2021;195:105182. doi:10.1016/j.antiviral.2021.105182.
  • Wittek R. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int J Infect Dis. 2006;10:193–201. doi:10.1016/j.ijid.2005.12.001.
  • Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MB, Duncan CJ, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis. 2022;22:1153–62. doi:10.1016/S1473-3099(22)00228-6.
  • Hammarlund E, Lewis MW, Carter SV, Amanna I, Hansen SG, Strelow LI, Wong SW, Yoshihara P, Hanifin JM, Slifka MK. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat Med. 2005;11:1005–11. doi:10.1038/nm1273.
  • Kozlov M. Monkeypox outbreaks: 4 key questions researchers have. Nature. 2022;606:238–9. doi:10.1038/d41586-022-01493-6.
  • Rao AK, Petersen BW, Whitehill F, Razeq JH, Isaacs SN, Merchlinsky MJ, Campos-Outcalt D, Morgan RL, Damon I, Sanchez PJ, et al. Use of JYNNEOS (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: recommendations of the advisory committee on immunization practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:734–42. doi:10.15585/mmwr.mm7122e1.
  • Seo SK, Liu C, Dadwal SS. Infectious disease complications in patients with cancer. Crit Care Clin. 2021;37:69–84. doi:10.1016/j.ccc.2020.09.001.
  • Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021;18:313–9. doi:10.1038/s41571-021-00487-z.
  • Hwang JK, Zhang T, Wang AZ, Li Z. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. J Hematol Oncol. 2021;14:38. doi:10.1186/s13045-021-01046-w.
  • Horowitz ME. The vaccine-hesitant moment. N Engl J Med. 2022;387:1050. doi:10.1056/NEJMc2210367.
  • Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, Srouji S, Sela E. Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol. 2020;35:775–9. doi:10.1007/s10654-020-00671-y.
  • Barriere J, Gal J, Hoch B, Cassuto O, Leysalle A, Chamorey E, Borchiellini D. Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey. Ann Oncol. 2021;32:673–4. doi:10.1016/j.annonc.2021.01.066.
  • de Sousa MJ, Caramujo C, Julio N, Magalhaes JC, Basto R, Fraga T, Gomes IF, Monteiro AR, Pazos I, Sousa G. Acceptance of SARS-CoV-2 vaccination among cancer patients in Portugal: attitudes and associated factors. Support Care Cancer. 2022;30:4565–70. doi:10.1007/s00520-022-06886-x.
  • Temsah MH, Aljamaan F, Alenezi S, Alhasan K, Saddik B, Al-Barag A, Alhaboob A, Bahabri N, Alshahrani F, Alrabiaah A, et al. Monkeypox caused less worry than COVID-19 among the general population during the first month of the WHO Monkeypox alert: experience from Saudi Arabia. Travel Med Infect Dis. 2022;49:102426. doi:10.1016/j.tmaid.2022.102426.
  • Hong J, Xu XW, Yang J, Zheng J, Dai SM, Zhou J, Zhang QM, Ruan Y, Ling CQ. Knowledge about, attitude and acceptance towards, and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China: a cross-sectional survey. J Integr Med. 2022;20:34–44. doi:10.1016/j.joim.2021.10.004.
  • Johnson P, Bergstrom CT, Regoes RR, Longini IM, Halloran ME, Antia R. Evolutionary consequences of delaying intervention for monkeypox. Lancet. 2022;400:1191–3. doi:10.1016/S0140-6736(22)01789-5.
  • Al KN, Zhang Y, Xia S, Yang Y, Al QM, Abdulrazzaq N, Al NM, Hassany M, Jawad JS, Abdalla J, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326:35–45. doi:10.1001/jama.2021.8565.
  • Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–54. doi:10.1016/S0140-6736(20)31208-3.
  • Prabani K, Weerasekara I, Damayanthi H. COVID-19 vaccine acceptance and hesitancy among patients with cancer: a systematic review and meta-analysis. Public Health. 2022;212:66–75. doi:10.1016/j.puhe.2022.09.001.
  • Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27:225–8. doi:10.1038/s41591-020-1124-9.
  • Villarreal-Garza C, Vaca-Cartagena BF, Becerril-Gaitan A, Ferrigno AS, Mesa-Chavez F, Platas A, Platas A. Attitudes and factors associated with COVID-19 vaccine hesitancy among patients with breast cancer. JAMA Oncol. 2021;7:1242–4. doi:10.1001/jamaoncol.2021.1962.
  • Han HJ, Nwagwu C, Anyim O, Ekweremadu C, Kim S. COVID-19 and cancer: from basic mechanisms to vaccine development using nanotechnology. Int Immunopharmacol. 2021;90:107247. doi:10.1016/j.intimp.2020.107247.
  • Hotez PJ. Anti-science extremism in America: escalating and globalizing. Microbes Infect. 2020;22:505–7. doi:10.1016/j.micinf.2020.09.005.
  • Hernandez RG, Hagen L, Walker K, O’Leary H, Lengacher C. The COVID-19 vaccine social media infodemic: healthcare providers’ missed dose in addressing misinformation and vaccine hesitancy. Hum Vaccine Immunother. 2021;17:2962–4. doi:10.1080/21645515.2021.1912551.
  • Laine C, Cotton D, Moyer DV. COVID-19 Vaccine: promoting vaccine acceptance. Ann Int Med. 2021;174:252–3. doi:10.7326/M20-8008.
  • Su M, Lao J, Zhang N, Wang J, Anderson RT, Sun X, Yao N. Financial hardship in Chinese cancer survivors. Cancer. 2020;126:3312–21. doi:10.1002/cncr.32943.
  • So WK, Ling GC, Choi KC, Chan CW, Wan RW, Mak SS, Sit JW. Comparison of health-related quality of life and emotional distress among Chinese cancer survivors. Int J Nurs Pract. 2013;19:306–17. doi:10.1111/ijn.12074.
  • Yasmin F, Najeeb H, Moeed A, Naeem U, Asghar MS, Chughtai NU, Yousaf Z, Seboka BT, Ullah I, Lin CY, et al. COVID-19 vaccine hesitancy in the United States: a systematic review. Front Public Health. 2021;9:770985. doi:10.3389/fpubh.2021.770985.
  • Determann D, de Bekker-Grob EW, French J, Voeten HA, Richardus JH, Das E, Korfage IJ. Future pandemics and vaccination: public opinion and attitudes across three European countries. Vaccine. 2016;34:803–8. doi:10.1016/j.vaccine.2015.12.035.
  • McClung N, Chamberland M, Kinlaw K, Matthew DB, Wallace M, Bell BP, Lee GM, Talbot HK, Romero JR, Oliver SE, et al. The Advisory Committee on immunization practices’ ethical principles for allocating initial supplies of COVID-19 Vaccine-United States, 2020. Am J Transplant. 2021;21:420–5. doi:10.1111/ajt.16437.
  • Petersen E, Kantele A, Koopmans M, Asogun D, Yinka-Ogunleye A, Ihekweazu C, Zumla A. Human Monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention. Infect Dis Clin North Am. 2019;33:1027–43. doi:10.1016/j.idc.2019.03.001.